Selection and Prioritization of Candidate Drug Targets for Amyotrophic Lateral Sclerosis Through a Meta-Analysis...

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with limited treatment options.
• Clinical trial failures in ALS are often attributed to inadequate animal models that do not fully represent human disease.
• Optimizing drug target selection requires identifying targets conserved between human pathology and preclinical models.

Purpose of the Study:

• To identify and prioritize potential therapeutic targets for sporadic ALS (SALS) by comparing human transcriptional profiles with those in a widely used mouse model.
• To assess the conservation of differentially expressed genes between human SALS motor cortex and SOD1 G93A mouse models.
• To evaluate the potential of identified targets for early diagnosis and therapy in ALS.

Main Methods:

• Transcriptional profiling of sporadic ALS patient motor cortex samples.
• Divergent subgroup analysis based on differentially expressed genes to identify 70 potential therapeutic targets.
• Interspecies comparison of human expression data with eight SOD1 G93A mouse datasets from public repositories.
• Analysis of target expression timing relative to disease onset.

Main Results:

• Identification of commonly deregulated targets and biological processes shared between human SALS and SOD1 G93A mouse models.
• Confirmation of conserved key drivers in both human and mouse ALS pathology.
• Demonstration that the majority of candidate targets are deregulated at the disease onset in both species.

Conclusions:

• The study highlights conserved molecular pathways and therapeutic targets between human ALS and the SOD1 G93A mouse model.
• Findings provide a basis for rational preclinical drug development in ALS by improving model relevance.
• Identified targets offer potential for earlier and more effective ALS diagnosis and therapeutic intervention.